Optimal Management of Extreme Obesity and Severe Knee Osteoarthritis Feasibility Trial
OMEOSKO
1 other identifier
interventional
20
1 country
1
Brief Summary
Does weight loss surgery in patients with morbid obesity prior to knee replacement surgery improve outcomes from knee replacement surgery
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable knee-osteoarthritis
Started Apr 2022
Longer than P75 for not_applicable knee-osteoarthritis
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 3, 2021
CompletedFirst Posted
Study publicly available on registry
November 15, 2021
CompletedStudy Start
First participant enrolled
April 22, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2027
August 21, 2024
August 1, 2024
5.2 years
November 3, 2021
August 19, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Pain, mobility and quality of Life
Knee Injury and Osteoarthritis Outcome Score (KOOS4)
1 year
Secondary Outcomes (1)
EuroQol Group 5-Dimension Self Report Questionnaire (EQ-5D)
1 year
Study Arms (2)
Surgical weight loss
EXPERIMENTALsleeve gastrectomy + dietary and lifestyle counseling prior to total knee replacement
Standard of Care
NO INTERVENTIONdietary and lifestyle counseling prior to total knee replacement
Interventions
The only intervention is the randomization of the priority of the 2 procedures.
Eligibility Criteria
You may qualify if:
- severe knee osteoarthritis body-mass index of 45 to 60
You may not qualify if:
- previous total replacement of the same knee, a need for bilateral total knee replacement, and knee pain during the previous week that the patient rated at higher than 60 mm on a 100-mm visual-analogue scale. Also,prior bariatric or complex foregut surgery, significant cardiovascular, pulmonary, renal, liver, gastrointestinal, psychiatric disorders, pregnancy, malignancy within last 5 years, anemia, coagulopathy requiring anti-coagulation therapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nova Scotia Health
Halifax, Nova Scotia, B4E 0H4, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 3, 2021
First Posted
November 15, 2021
Study Start
April 22, 2022
Primary Completion (Estimated)
July 1, 2027
Study Completion (Estimated)
July 1, 2027
Last Updated
August 21, 2024
Record last verified: 2024-08